← Leaderboards
Hema Adhikari
Washington University
$937,574
Attributed
$937,574
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $249K · FY2020–25$250K$187.5K$125K$62.5K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$937,574 · 2
By mechanism
R00$746,222 · 1
K99$191,352 · 1
Top collaborators
No co-investigators on record.
Most similar at Washington University
Same institution · by research overlap
- Kian H Lim$7,461,157
- Maurine E Linder$5,129,444
- Megan Deanna Radyk$377,301
- Ross Leigh Cagan$25,056,984
- Courtney Wayne Houchen$10,004,858
Others in their field
Other Emerging Leaders on “Antineoplastic Agents”
- Leonard Freedman · Leidos Biomedical Research, Inc.$243,278,693
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,166,869
- Leonard Freedmand · Leidos Biomedical Research, Inc.$54,796,285
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$29,626,259
- James Jeffrey Sahn · 4e Therapeutics Inc.$7,126,294
- Jeffrey H. Price · Vala Sciences, Inc.$5,562,326
Research focus
Antineoplastic AgentsAutomobile DrivingBindingBiochemicalCancer CellCell FractionationCell GrowthCell TransformationCrispr/Cas TechnologyCultured CellsData SetDependenceDrug TargetingEnhancersExperimental StudyFutureGenesGeneticGenetically Engineered MouseGenotypeGrantHomeostasisImmunotherapyAblation
Grant awards (5)
Interrogating the RAS interactome for therapeutic vulnerabilities$248,999
R00 · FY2025 · CA · contact PI
Interrogating the RAS interactome for therapeutic vulnerabilities$248,999
R00 · FY2024 · CA · contact PI
Interrogating the RAS interactome for therapeutic vulnerabilities$248,224
R00 · FY2023 · CA · contact PI
Interrogating the RAS interactome for therapeutic vulnerabilities$96,756
K99 · FY2021 · CA · contact PI
Interrogating the RAS interactome for therapeutic vulnerabilities$94,596
K99 · FY2020 · CA · contact PI